Newtopia Reports Record Third Quarter 2020 Financial Results

Quarterly Revenue and gross profit increased 99% and 182% year-over-year; expanding client list and leadership team

TORONTO, Nov. 12, 2020 /CNW/ – Newtopia Inc. (“Newtopia” or the “Company“) (TSXV: NEWU), a tech-enabled disease prevention company focused on healthy habit change, today reported financial results for its third quarter 2020.

“2020 has been a monumental year for Newtopia. We’ve seen continued adoption with Fortune 50 and Fortune 500 innovators, added important talent in both leadership and data science roles and delivered strong revenue and gross margin growth,” said Jeff Ruby, Founder & CEO, Newtopia Inc. “On a year to date basis, revenue and gross profit are up 96% and 133% respectively over 2019. We are incredibly pleased with our growth to date and feel that the talent we have added strengthens us operationally in key areas of the Company.”

All amounts are expressed in Canadian dollars.

Third Quarter 2020 Financial Highlights (vs. Q3 2019):

  • Revenue increased 99% to $2.4 million
  • Gross profit1 increased 182%, to $1.2 million
  • Gross margin percentage improves to 49%, up from 35%


Recent Operational Highlights:

  • Announced closing of an oversubscribed and upsized $7.5 million bought deal offering, and signed binding agreement for $5 million operating facility with a leading Canadian schedule 1 bank
  • Released product suite to prevent, reverse and slow the progression of chronic disease with large employer and health plan populations
  • Expanded client list with addition of new Fortune 50 innovator
  • Added multiple data science experts to deepen strength in analytics and outcomes measurement, and key leaders to the Newtopia team, board and advisory board

 

“We’re continuing to see strong engagement levels as our client organizations and their employees recognize the value of our tech-enabled service and habit-changing platform throughout the pandemic, with over 90% of our revenue coming from engagement fees in the quarter,” adds Ruby. “With both an oversubscribed and upsized bought deal offering completed and a substantial new operating facility recently secured, Newtopia has bolstered its balance sheet with the financial resources to continue to innovate for our clients and their employees.”


1 Gross profit is defined as revenue which is comprised of onboarding welcome revenue, ongoing engagement fees and success fees, less cost of sales which is comprised of welcome kit, compensation expense for inspirators and care specialists and genetic testing costs. Gross profit is considered by management to be an integral measure of financial performance and represents the amount of revenues retained by the Company after incurring direct costs. However, gross profit is not a recognized measure of profitability under IFRS.

Newtopia’s platform leverages genetic, social and behavioral insights to create individualized prevention programs with a focus on type 2 diabetes, heart disease, stroke and weight. The Company’s individualized approach combines virtual care, digital tools, connected devices and actionable data science to deliver sustainable clinical and financial outcomes.

Third Quarter 2020 Financial Results

Newtopia’s revenue during the three months ended September 30, 2020 was $2.4 million, an increase of 99% over the prior period ($1.2 million). This growth reflected a continuation of strong engagement fee revenue from the Q1 program launch with a highly innovative existing Fortune 500 partner.

Gross profit for the three months ended September 30, 2020 increased by 182% to $1.2 million over the prior year period ($0.4 million). Strong engagement revenue in the quarter offset cost of sales coming from higher Inspirator (coach) costs, as overall margin improved to 49% over the prior year level of 35%. Engagement fee revenue made up over 90% of the revenue mix in the current year quarter as compared to approximately 85% in the same period for 2019, accounting for the overall improvement in margin.

Adjusted operating expenses2 in the three months ended September 30, 2020 increased by 52% to $2.5 million over the prior year period ($1.7 million) as the Company continued to add technology, sales and marketing and administrative resources in support of longer-term company growth. The Company continues to take a measured approach to adding expenses in support of growth, as increases in these line items has been more modest than growth in revenue and gross profit. Overall, the Company had an adjusted operating loss3 of $1.4 million in the quarter, compared to a loss of $1.3 million in the prior year period.


2 Adjusted operating expenses consist of all cash-based technology, sales and marketing and administrative expenses including employment expenses for these functions excluding equity-settled share-based compensation. Adjusted operating expense is not a measure of financial performance under IFRS and should not be considered a substitute for total operating expenses, which we believe to be the most directly comparable IFRS measure.

3 Adjusted Operating Loss consists of Gross profit less adjusted operating income. Adjusted operating loss is not a measure of financial performance under IFRS and should not be considered a substitute for Loss from Operations which we believe to be the most directly comparable IFRS measure.

About Newtopia

Newtopia is a tech-enabled disease prevention company focused on healthy habit change. Newtopia’s platform leverages genetic, social and behavioral insights to create individualized prevention programs with a focus on type 2 diabetes, heart disease, stroke and weight. Our person-centered approach combines virtual care, digital tools, connected devices and actionable data science to deliver sustainable clinical and financial outcomes. We serve some of the largest nationwide employers and health plans. To learn more, visit newtopia.com.

Forward Looking Information

This press release contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, and forward looking statements, within the meaning of applicable United States securities legislation (collectively, “forward-looking statements“), which reflects management’s expectations regarding Newtopia’s future growth, results from operations (including, without limitation, future production and capital expenditures), performance (both operational and financial) and business prospects and opportunities. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation or other variations thereof, or comparable terminology have been used to identify forward-looking statements. All statements other than statements of historical fact may be forward-looking ‎information. Such statements reflect Newtopia’s current views and intentions with respect to future ‎events, based on information available to Newtopia, and are subject to certain risks, uncertainties and ‎assumptions, including without limitation, the Company’s successful completion of the bank financing and current financial trends remaining at or above the current levels in respect of revenue, gross profit, gross margin percentage and adjusted operating expenses. Material factors or assumptions were applied in providing forward-looking information. While forward-looking statements are based on data, assumptions and analyses that Newtopia believes are reasonable under the circumstances, whether actual results, performance or developments will meet Newtopia’s expectations and predictions depends on a number of risks and uncertainties that could cause the actual results, performance and financial condition of Newtopia to differ materially from its expectations. These forward-looking statements include, among other things, clients continuing to offer Newtopia’s platform pursuant to agreements entered into, the timing and ability of the Company to complete the bank credit facility, the Company being confident that it will continue to increase its revenue, gross profit, gross margin percentage and adjusted operating expenses among other financial metrics and current financial trends remaining at or above current levels. Forward-looking statements are not a guarantee and are based on a number of estimates and assumptions management believes to be relevant and reasonable, whether actual results, performance or developments will meet Newtopia’s expectations and predictions depends on a number of risks and uncertainties that could cause the actual results, performance and financial condition of Newtopia to differ materially from its expectations. Certain of the “risk factors” that could cause ‎actual results to differ materially from Newtopia’s forward-looking statements in this press release ‎include, without limitation: the termination of contracts by clients, risks related to COVID-19 including various recommendations, orders and measures of ‎‎governmental authorities to try to limit the pandemic, including travel restrictions, border closures, ‎‎non-essential business closures, quarantines, self-isolations, shelters-in-place and social ‎distancing, ‎disruptions to markets, economic activity, financing, supply chains and sales channels, ‎and a ‎deterioration of general economic conditions including a possible national or global ‎recession; and other general economic, market and business conditions and factors, including the risk factors discussed or referred to in Newtopia’s disclosure documents, filed with the securities ‎regulatory authorities in certain provinces of Canada and available at www.sedar.com including Newtopia’s final long form prospectus dated March 30, 2020.

Should any factor affect Newtopia’s in an unexpected manner, or should assumptions underlying the forward- looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, Newtopia does not assume responsibility for the accuracy or completeness of such forward-looking information. The forward-looking information included in this press release is made as of the date of this press release, and Newtopia undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law.

Non-GAAP Financial Measures

The Company’s financial statements are prepared in accordance with International Financial Reporting Standards (“IFRS”). Management uses certain non-GAAP measures, which are defined in the appropriate sections of this press release, to better assess the Company’s underlying performance. These measures are reviewed regularly by management and the Company’s Board of Directors in assessing the Company’s performance and in making decisions about ongoing operations. In addition, we use certain non-GAAP measures to determine the components of management compensation. We believe that these measures are also used by investors as an indicator of the Company’s operating performance. Readers are cautioned that these terms are not recognized GAAP measures and do not have a standardized GAAP meaning under IFRS and should not be construed as alternatives to IFRS terms, such as net income.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information: Chief Executive Officer: Jeff Ruby, jruby@newtopia.com; Media Contact: Rikki Bennie, rbennie@newtopia.com, 1.888.639.8181 ext 208

NEWTOPIA INC.

Key Financial Measures and Schedule of Non-GAAP Reconciliations

Gross Profit Information [1]

Three Months Ended

September 30,

Nine Months Ended

September 30,

2020

2019

2020

2019

$

$

$

$

Revenue

2,389,374

1,201,893

8,939,415

4,571,597

Cost of sales

(1,213,393)

(784,342)

(4,698,576)

(2,749,430)

Gross profit

1,175,981

417,551

4,240,839

1,822,167

Gross margin

49%

35%

47%

40%

[1] Gross profit is defined as revenue which is comprised of onboarding welcome revenue, ongoing engagement fees and success fees, less cost of sales which is comprised of welcome kit, compensation expense for inspirators and care specialists and genetic testing costs. Gross profit is considered by management to be an integral measure of financial performance and represents the amount of revenues retained by the Company after incurring direct costs. However, gross profit is not a recognized measure of profitability under IFRS

Reconciliation of Total Operating Expenses to Adjusted Operating Expenses [2]

Three Months Ended

September 30,

Nine Months Ended

September 30,

2020

2019

2020

2019

$

$

$

$

Total operating expenses

2,931,316

2,737,399

9,044,293

7,883,485

Add (Subtract)

Share-based compensation

(120,528)

(226,848)

(376,619)

(564,574)

Depreciation of property and equipment

(19,012)

(13,827)

(61,905)

(37,396)

Depreciation of right-of-use asset

(46,192)

(46,192)

(138,578)

(138,576)

Interest and accretion expense

(718,609)

(233,542)

(2,162,526)

Interest on lease obligations

(35,269)

(39,591)

(109,967)

(119,867)

Interest on promissory note

(8,219)

(8,219)

Finance charges

(10,995)

Foreign exchange gain

(39,778)

22,593

56,713

358

Change in value of convertible debenture derivative liabilities

(19,980)

(448,656)

(86,097)

Change in value of derivative liability

(111,680)

(25,398)

(63,804)

(27,874)

Loss on settlement of debt

(167,716)

Adjusted operating expenses

2,539,643

1,669,547

7,492,000

4,746,933

[2] Adjusted operating expenses consist of all cash-based technology, sales and marketing and administrative expenses including employment expenses for these functions excluding equity-settled share-based compensation. Adjusted operating expense is not a measure of financial performance under IFRS and should not be considered a substitute for total operating expenses, which we believe to be the most directly comparable IFRS measure.

NEWTOPIA INC.

Key Financial Measures and Schedule of Non-GAAP Reconciliations

Adjusted Operating Loss [3]

Three Months Ended

September 30,

Nine Months Ended

September 30,

2020

2019

2020

2019

$

$

$

$

Gross profit

1,175,981

417,551

4,240,839

1,822,167

Adjusted operating expenses

(2,539,643)

(1,669,547)

(7,492,000)

(4,746,933)

(1,363,662)

(1,251,996)

(3,251,161)

(2,924,766)

[3] Adjusted Operating Loss consists of Gross profit less adjusted operating income. Adjusted operating loss is not a measure of financial performance under IFRS and should not be considered a substitute for Loss from Operations which we believe to be the most directly comparable IFRS measure.

NEWTOPIA INC.

Condensed Interim Statements of Financial Position (Unaudited)

As at September 30, 2020 and December 31, 2019

(Expressed in Canadian Dollars)

September 30,

2020

December 31,

2019

$

$

Assets

Current assets

Cash

660,845

2,386,341

Trade and other receivables

838,860

1,247,858

Prepaid expenses and deposits

509,749

462,605

Inventories

223,662

604,920

2,233,116

4,701,724

Property and equipment

140,196

186,376

Right‑of‑use asset

600,494

739,072

2,973,806

5,627,172

Liabilities

Current liabilities

Accounts payable and accrued liabilities

1,689,224

2,254,894

Lease obligations

203,523

156,340

Promissory note

500,000

Convertible debentures

3,993,758

Convertible debentures derivative liabilities

1,952,638

Retractable preferred shares

7,420,265

Derivative liability

242,474

178,670

2,635,221

15,956,565

Non‑current lease obligations

731,828

883,090

3,367,049

16,839,655

Equity/Deficit

Common shares

38,804,666

4,643,945

Shares to be issued

528,168

Preferred shares

13,011,033

Special warrants

9,164,731

Contributed surplus

8,369,411

5,172,192

Deficit

(48,095,488)

(43,204,384)

(393,243)

(11,212,483)

2,973,806

5,627,172

NEWTOPIA INC.

Condensed Interim Statements of Loss and Comprehensive Loss (Unaudited)

Three and Nine Months Ended September 30, 2020 and 2019

(Expressed in Canadian Dollars)

Three Months Ended

Nine Months Ended

September 30,

September 30,

2020

2019

2020

2019

$

$

$

$

Revenue

2,389,374

1,201,893

8,939,415

4,571,597

Cost of revenue

1,213,393

784,342

4,698,576

2,749,430

Gross profit

1,175,981

417,551

4,240,839

1,822,167

Operating expenses

Technology and development

812,228

582,666

2,382,216

1,686,016

Sales and marketing

781,307

407,963

2,324,985

1,195,733

Administrative

946,108

678,918

2,773,804

1,865,184

Share‑based compensation

120,528

226,848

376,619

564,574

2,660,171

1,896,395

7,857,624

5,311,507

Other expenses (income)

Depreciation of property and equipment

19,012

13,827

61,905

37,396

Depreciation of right‑of‑use asset

46,192

46,192

138,578

138,576

Interest and accretion expense

718,609

233,542

2,162,526

Interest on lease obligations

35,269

39,591

109,967

119,867

Interest on promissory note

8,219

8,219

Finance charges

10,995

10,995

Foreign exchange gain

39,778

(22,593)

(56,713)

(358)

Change in value of convertible debentures derivative liabilities

19,980

448,656

86,097

Change in value of derivative liability

111,680

25,398

63,804

27,874

Loss on settlement of debt

167,716

271,145

841,004

1,186,669

2,571,978

Net loss and comprehensive loss

(1,755,335)

(2,319,848)

(4,803,454)

(6,061,318)

Loss per share

Basic and diluted

(0.02)

(0.15)

(0.09)

(0.39)

Weighted average number of common shares outstanding

Basic and diluted

91,010,143

15,535,919

56,464,872

15,535,919

NEWTOPIA INC.

Condensed Interim Statements of Changes in Equity (Deficit) (Unaudited)

Nine Months Ended September 30, 2020 and 2019

(Expressed in Canadian Dollars)

Note

Common Shares

Shares To Be Issued

Preferred Shares

Special Warrants

Contributed Surplus

Deficit

Total

$

$

$

$

$

$

$

Balance, December 31, 2019

4,643,945

13,011,033

9,164,731

5,172,192

(43,204,384)

(11,212,483)

Net loss and comprehensive loss

(4,803,454)

(4,803,454)

Share‑based compensation

376,619

376,619

Conversion of Convertible Debentures

6

6,039,000

589,594

6,628,594

Modification of warrants

8(e)

87,650

(87,650)

Conversion of retractable preferred shares

7

7,420,265

7,420,265

Conversion of preferred shares

8(c)

13,011,033

(13,011,033)

Conversion of Special warrants

9

6,812,648

(9,164,731)

2,352,083

Settlement of debt

11,12

528,168

39,548

567,716

Exercise of warrants

8(e)

877,775

(248,275)

629,500

Balance, September 30, 2020

38,804,666

528,168

8,369,411

(48,095,488)

(393,243)

Balance, December 31, 2018

4,643,945

13,011,033

2,701,639

(32,799,372)

(12,442,755)

Net loss and comprehensive loss

(6,061,318)

(6,061,318)

Share‑based compensation

564,574

564,574

Issuance of Special Warrants, net of cash issuance costs

9

7,771,513

7,771,513

Special Broker Warrants issued

9

(181,351)

181,351

Balance, September 30, 2019

4,643,945

13,011,033

7,590,162

3,447,564

(38,860,690)

(10,167,986)

NEWTOPIA INC.

Condensed Interim Statements of Cash Flows (Unaudited)

Nine Months Ended September 30, 2020 and 2019

(Expressed in Canadian Dollars)

Nine Months Ended September 30,

2020

2019

Cash flows used in operating activities:

$

$

Net loss and comprehensive loss

(4,803,454)

(6,061,318)

Items not involving cash:

Depreciation of property and equipment

61,905

37,396

Depreciation of right‑of‑use asset

138,578

138,576

Share‑based compensation

376,619

564,574

Interest and accretion expense

233,542

2,162,526

Interest on lease obligations

109,967

119,867

Interest on promissory note

8,219

Loss on settlement of debt

167,716

Change in value of convertible debentures derivative liabilities

448,656

86,097

Change in value of derivative liability

63,804

27,874

(3,194,448)

(2,924,408)

Net change in non‑cash working capital

Trade and other receivables

408,998

(716,821)

Inventories

381,258

100,137

Prepaid expenses and deposits

(47,144)

(111,359)

Accounts payable and accrued liabilities

(173,889)

116,176

(2,625,225)

(3,536,275)

Interest paid

(1,944)

(2,625,225)

(3,538,219)

Cash flows used in investing activities

Purchase of property and equipment

(15,725)

(21,636)

(15,725)

(21,636)

Cash flows from (used in) financing activities:

Repayment of lease obligations

(214,046)

(142,525)

Issuance of Special Warrants, net of cash issuance costs and settlement of Debentures

7,021,513

Proceeds from promissory note

500,000

Proceeds from exercise of non‑broker warrants

629,500

915,454

6,878,988

(Decrease) increase in cash

(1,725,496)

3,319,133

Cash, beginning of period

2,386,341

1,428,558

Cash, end of period

660,845

4,747,691

Supplemental disclosure of cash flow information

Non‑cash settlement of secured debentures

750,000

Scroll to Top